Cite
Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation
MLA
J. Steininger, et al. “Efficacy of BRAF/MEK-Inhibitor Therapy for Epithelioid Glioblastoma with a Novel BRAFV600 Mutation.” Acta Neuropathologica Communications, vol. 12, no. 1, Aug. 2024, pp. 1–12. EBSCOhost, https://doi.org/10.1186/s40478-024-01834-8.
APA
J. Steininger, C. Buszello, R. Oertel, M. Meinhardt, S. Schmid, K. Engellandt, S. Herold, S. Stasik, A. Ebrahimi, B. Renner, C. Thiede, I.Y. Eyüpoglu, G. Schackert, S. Beissert, F. Meier, J. Radke, D. Westphal, & T. A. Juratli. (2024). Efficacy of BRAF/MEK-inhibitor therapy for epithelioid glioblastoma with a novel BRAFV600 mutation. Acta Neuropathologica Communications, 12(1), 1–12. https://doi.org/10.1186/s40478-024-01834-8
Chicago
J. Steininger, C. Buszello, R. Oertel, M. Meinhardt, S. Schmid, K. Engellandt, S. Herold, et al. 2024. “Efficacy of BRAF/MEK-Inhibitor Therapy for Epithelioid Glioblastoma with a Novel BRAFV600 Mutation.” Acta Neuropathologica Communications 12 (1): 1–12. doi:10.1186/s40478-024-01834-8.